Amur Minerals (GB:CRTX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CRISM Therapeutics Corporation has been awarded an Innovation Passport for their ChemoSeed product for high grade gliomas by the UK’s MHRA, expediting the treatment’s development and access. Additionally, the company has received a £25,000 grant from SPARK The Midlands to further support their innovative cancer treatment technology. The CEO, Andrew Webb, highlighted these recognitions as significant milestones and endorsements for the potential of ChemoSeed to transform brain tumour treatments.
For further insights into GB:CRTX stock, check out TipRanks’ Stock Analysis page.